Welcome to our dedicated page for VERACYTE SEC filings (Ticker: VCYT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Veracyte, Inc. filings document the regulatory record for a Nasdaq-listed cancer diagnostics company with a portfolio that includes Decipher, Afirma, Prosigna, and bladder cancer diagnostics. The company’s Form 8-K reports primarily cover operating and financial results, preliminary financial and testing-volume estimates, and material corporate events.
Veracyte’s proxy and governance filings disclose shareholder voting matters, board and executive compensation practices, equity award information, and governance procedures. Other material-event filings address officer appointments, compensatory arrangements, capital-structure disclosures, and formal exhibits tied to financial reporting and corporate actions.
Veracyte, Inc. Chief Commercial Officer-CLIA John Leite reported an automatic share disposition related to tax withholding. On March 2, 2026, 7,517 shares of common stock were withheld at a price of $36.01 per share to cover taxes on vesting restricted stock units, leaving him with 112,840 directly owned shares. The filing specifies this did not represent an open-market sale.
Veracyte, Inc. executive Phillip G. Febbo reported two stock transactions on March 2, 2026. The company withheld 6,035 shares of common stock at $36.01 per share to cover his tax obligations from vesting restricted stock units, which is not a market sale. He also completed an open-market sale of 13,425 shares at a weighted average price of $36.1586 per share under a pre-arranged Rule 10b5-1 trading plan. After these transactions, he directly owned 117,346 shares of Veracyte common stock.
VERACYTE, INC. Chief Executive Officer Marc Stapley reported a tax-related share disposition. On March 2, 2026, 19,455 shares of common stock were withheld to satisfy tax obligations tied to vesting restricted stock units at a reference price of $36.01 per share. Following this withholding, he directly owns 403,077 shares of Veracyte common stock. The footnote clarifies this was not an open-market sale but a tax-withholding transaction.
Veracyte, Inc. Chief Commercial Officer-CLIA John Leite reported equity-related transactions in company common stock. He acquired 47,149 shares on February 26, 2026 from vesting of performance-based restricted stock units after the board certified achievement of performance goals. On the same date, 8,905 shares were disposed at $38.75 per share to cover tax withholding obligations tied to this vesting, which the disclosure states does not represent a sale. Following these transactions, he directly owned 120,357 shares of Veracyte common stock.
Veracyte, Inc. Chief Executive Officer Marc Stapley reported equity compensation activity involving the company’s common stock. He acquired 139,074 shares on February 26, 2026 through the vesting of performance-based restricted stock units after the board certified achievement of required performance goals. Of these units, 70,239 PSUs vested immediately, while 68,835 PSUs are scheduled to vest on December 2, 2026, contingent on his continued service. To cover tax withholding obligations from this vesting, 35,841 shares were withheld at $38.75 per share, which the filing states does not represent an open-market sale. Following these transactions, Stapley directly held 422,532 shares of Veracyte common stock.
Veracyte, Inc. Chief Financial Officer Rebecca Chambers reported equity compensation activity involving the company’s common stock. On February 26, 2026, she acquired 59,324 shares at no cost upon vesting of performance-based restricted stock units after the board certified achievement of performance goals. On the same date, 12,049 shares were withheld at a price of $38.75 per share to cover tax obligations related to this vesting, which the company notes does not represent a sale. Following these transactions, Chambers directly owned 156,771 shares of Veracyte common stock.
VERACYTE, INC. reported an equity award transaction for Chief Scientific & Med Officer Phillip G. Febbo. On February 26, 2026, he acquired 71,806 shares of common stock at $0.00 per share through the vesting of performance-based restricted stock units. According to the award terms, 47,863 PSUs vested on that date and 23,943 additional PSUs are scheduled to vest on December 2, 2026, subject to continued service. To cover tax withholding from the vesting, 24,486 shares were withheld at $38.75 per share, a disposition that did not involve an open-market sale. Following these transactions, he directly owned 136,806 common shares.
Veracyte, Inc. reported that SVP and General Counsel Annie McGuire acquired 50,999 shares of common stock through the vesting of performance-based restricted stock units on February 26, 2026. According to the filing, 21,071 PSUs vested on that date, with 29,928 additional PSUs scheduled to vest on December 2, 2026, subject to her continued service.
The filing also notes that 10,867 shares were withheld to cover tax obligations related to the PSU vesting, which is characterized as a tax-withholding disposition rather than an open-market sale. After these transactions, McGuire directly owned 108,266 shares of Veracyte common stock, including 374 shares purchased earlier under the company’s employee stock purchase plan.
Veracyte, Inc. outlines its role as a global cancer diagnostics company focused on high‑value molecular tests that help personalize treatment decisions. The business centers on laboratory developed tests in the U.S. and in vitro diagnostic kits internationally, with major revenue from Decipher Prostate and Afirma.
The company is investing in growth drivers including its TrueMRD minimal residual disease platform, expansion of Prosigna breast cancer testing as a U.S. lab-developed test and as an IVD globally, and the Percepta Nasal Swab test for lung nodule assessment. Its Veracyte Diagnostics Platform combines whole‑transcriptome and whole‑genome technologies, AI, and extensive evidence generation to secure reimbursement and guideline inclusion.
Veracyte details broad Medicare and commercial coverage for key assays, notes that Medicare fee‑for‑service represented 34% of 2025 testing revenue while private payers contributed 47%, and explains complex U.S., EU, UK and data‑privacy regulatory frameworks governing its labs, tests, and patient information.